NASDAQ:AUPH Aurinia Pharmaceuticals (AUPH) Stock Price, News & Analysis $5.43 -0.06 (-1.09%) (As of 07/2/2024 ET) Add Compare Share Share Today's Range$5.42▼$5.5550-Day Range$4.87▼$5.7852-Week Range$4.71▼$12.43Volume567,062 shsAverage Volume1.84 million shsMarket Capitalization$774.64 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Aurinia Pharmaceuticals alerts: Email Address Aurinia Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside84.2% Upside$10.00 Price TargetShort InterestBearish7.14% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.11Based on 5 Articles This WeekInsider TradingN/AProj. Earnings Growth253.33%From $0.15 to $0.53 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.83 out of 5 starsMedical Sector634th out of 914 stocksPharmaceutical Preparations Industry290th out of 433 stocks 3.4 Analyst's Opinion Consensus RatingAurinia Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAurinia Pharmaceuticals has received no research coverage in the past 90 days.Read more about Aurinia Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.14% of the outstanding shares of Aurinia Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAurinia Pharmaceuticals has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Aurinia Pharmaceuticals has recently increased by 10.53%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAurinia Pharmaceuticals does not currently pay a dividend.Dividend GrowthAurinia Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AUPH. Previous Next 2.8 News and Social Media Coverage News SentimentAurinia Pharmaceuticals has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Aurinia Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 10 people have searched for AUPH on MarketBeat in the last 30 days. This is a decrease of -23% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Aurinia Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aurinia Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.30% of the stock of Aurinia Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 36.83% of the stock of Aurinia Pharmaceuticals is held by institutions.Read more about Aurinia Pharmaceuticals' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Aurinia Pharmaceuticals are expected to grow by 253.33% in the coming year, from $0.15 to $0.53 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aurinia Pharmaceuticals is -12.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aurinia Pharmaceuticals is -12.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAurinia Pharmaceuticals has a P/B Ratio of 2.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Aurinia Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Digital Mavericks Media1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income every month.Click here to check it out. About Aurinia Pharmaceuticals Stock (NASDAQ:AUPH)Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Read More AUPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AUPH Stock News HeadlinesJune 14, 2024 | businesswire.comAurinia Announces 2024 Annual General Meeting ResultsJune 5, 2024 | businesswire.comAurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024July 3, 2024 | Stansberry Research (Ad)25th AmendmentIt's not surprising that talk of invoking the 25th Amendment (to remove Biden from office) has surfaced.May 30, 2024 | businesswire.comAurinia Will Attend 2024 Jefferies Global Healthcare ConferenceMay 26, 2024 | finance.yahoo.comShareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) have lost 64%, as stock drops 9.5% this past weekMay 14, 2024 | finance.yahoo.comAnalysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024May 14, 2024 | businesswire.comAnalysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation's Spring Clinical Meeting 2024May 13, 2024 | stocknews.comTop 4 Pharma Stocks to Consider This MonthJuly 3, 2024 | Stansberry Research (Ad)25th AmendmentIt's not surprising that talk of invoking the 25th Amendment (to remove Biden from office) has surfaced.May 9, 2024 | finance.yahoo.comAurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024May 7, 2024 | businesswire.comAurinia Pharmaceuticals Shareholder Urges Board of Directors to Take Action to Enhance Shareholder ValueMay 7, 2024 | businesswire.comAurinia Will Attend 2024 RBC Capital Markets Global Healthcare ConferenceMay 2, 2024 | seekingalpha.comAurinia Pharmaceuticals Inc. (AUPH) Q1 2024 Earnings Call TranscriptMay 2, 2024 | markets.businessinsider.comLeerink Partners Keeps Their Buy Rating on Aurinia Pharmaceuticals (AUPH)May 2, 2024 | businesswire.comAurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational ResultsMay 1, 2024 | markets.businessinsider.comAurinia Pharmaceuticals is about to announce earnings — here's what Wall Street expectsMay 1, 2024 | businesswire.comAurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness MonthApril 30, 2024 | seekingalpha.comAurinia: Updated Lupkynis Label Should Keep Sales Growth Momentum GoingApril 30, 2024 | businesswire.comThe U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical ProgramApril 18, 2024 | seekingalpha.comAurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024April 16, 2024 | businesswire.comUPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 15, 2024 | businesswire.comAurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024April 9, 2024 | businesswire.comAurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 9, 2024 | sg.finance.yahoo.comBRIEF-Soilbuild Construction Says Group Awarded New ContractsApril 7, 2024 | finance.yahoo.comWhen Will Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Breakeven?March 17, 2024 | finance.yahoo.com11 Oversold Biotech Stocks To Buy Right NowMarch 14, 2024 | finance.yahoo.comAUPH Mar 2024 3.000 callSee More Headlines Receive AUPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/02/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AUPH CUSIPN/A CIK1600620 Webwww.auriniapharma.com Phone250-708-4272Fax250-744-2498Employees300Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$13.00 Low Stock Price Target$8.00 Potential Upside/Downside+84.2%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.43) Trailing P/E RatioN/A Forward P/E Ratio36.20 P/E GrowthN/ANet Income$-78,020,000.00 Net Margins-32.69% Pretax Margin-32.24% Return on Equity-15.06% Return on Assets-10.57% Debt Debt-to-Equity Ratio0.19 Current Ratio5.60 Quick Ratio5.05 Sales & Book Value Annual Sales$175.51 million Price / Sales4.41 Cash FlowN/A Price / Cash FlowN/A Book Value$2.63 per share Price / Book2.06Miscellaneous Outstanding Shares142,660,000Free Float136,529,000Market Cap$774.64 million OptionableOptionable Beta1.44 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Peter S. Greenleaf M.B.A. (Age 54)President, CEO & Director Comp: $1.34MMr. Joseph M. Miller CPA (Age 50)Chief Financial Officer Comp: $791.92kMr. Matthew Maxwell Donley M.B.A. (Age 55)Executive Vice President of Operations & Strategy Comp: $811.82kMr. Stephen P. Robertson (Age 42)Executive VP, General Counsel, Corporate Secretary & Chief Compliance Officer Comp: $739.68kDr. Volker Knappertz D.Sc. (Age 59)M.D., Executive Vice President of Research & Development Comp: $742.85kAndrea Levin ChristopherHead of the Corporate Communications & Investor RelationsMr. Fran LynchVice President of SalesMr. Michael R. Martin (Age 52)Chief Business Officer Comp: $350.57kMs. Sue EvansSenior Vice President of Global Regulatory AffairsMr. Scott Habig (Age 64)Chief Commercial Officer More ExecutivesKey CompetitorsY-mAbs TherapeuticsNASDAQ:YMABIGM BiosciencesNASDAQ:IGMSCryoportNASDAQ:CYRXAmarinNASDAQ:AMRNMyovant SciencesNYSE:MYOVView All CompetitorsInstitutional OwnershipDekaBank Deutsche GirozentraleSold 11,608 shares on 6/4/2024Ownership: 0.005%Cetera Advisors LLCBought 9,547 shares on 5/24/2024Ownership: 0.042%Virtu Financial LLCBought 15,591 shares on 5/20/2024Ownership: 0.011%Walleye Trading LLCBought 200 shares on 5/17/2024Ownership: 0.000%California State Teachers Retirement SystemSold 7,313 shares on 5/16/2024Ownership: 0.096%View All Institutional Transactions AUPH Stock Analysis - Frequently Asked Questions Should I buy or sell Aurinia Pharmaceuticals stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AUPH shares. View AUPH analyst ratings or view top-rated stocks. What is Aurinia Pharmaceuticals' stock price target for 2024? 4 brokerages have issued 12 month price objectives for Aurinia Pharmaceuticals' shares. Their AUPH share price targets range from $8.00 to $13.00. On average, they expect the company's share price to reach $10.00 in the next year. This suggests a possible upside of 84.2% from the stock's current price. View analysts price targets for AUPH or view top-rated stocks among Wall Street analysts. How have AUPH shares performed in 2024? Aurinia Pharmaceuticals' stock was trading at $8.99 at the start of the year. Since then, AUPH stock has decreased by 39.6% and is now trading at $5.43. View the best growth stocks for 2024 here. Are investors shorting Aurinia Pharmaceuticals? Aurinia Pharmaceuticals saw a increase in short interest in June. As of June 15th, there was short interest totaling 10,180,000 shares, an increase of 10.5% from the May 31st total of 9,210,000 shares. Based on an average daily trading volume, of 1,280,000 shares, the short-interest ratio is presently 8.0 days. View Aurinia Pharmaceuticals' Short Interest. When is Aurinia Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our AUPH earnings forecast. How were Aurinia Pharmaceuticals' earnings last quarter? Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) issued its quarterly earnings data on Thursday, May, 2nd. The biotechnology company reported ($0.03) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.14. The biotechnology company had revenue of $50.30 million for the quarter, compared to analyst estimates of $46.30 million. Aurinia Pharmaceuticals had a negative trailing twelve-month return on equity of 15.06% and a negative net margin of 32.69%. What ETF holds Aurinia Pharmaceuticals' stock? Virtus LifeSci Biotech Products ETF holds 61,561 shares of AUPH stock, representing 1.66% of its portfolio. What other stocks do shareholders of Aurinia Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Exelixis (EXEL), AbbVie (ABBV), Amarin (AMRN) and Array Technologies (ARRY). How do I buy shares of Aurinia Pharmaceuticals? Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AUPH) was last updated on 7/3/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredRe: We’re giving you all this for less than a pair of socksThe Only Trading Tool You'll Need This Year Forget juggling multiple subscriptions and confusing indicator...StockEarnings | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredBuy this small stock before coming AI Tidal WaveThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of ne...Chaikin Analytics | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe End of Privacy for Americans… Get Out of Cash Now!Unlock the Secret to Outsmarting Inflation with "The Trump Loophole" That investment? Gold.Golden Crest | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aurinia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
